Our partnerships

We know we can’t reach our goal of improving patient access to much needed biologics without help, so we have partnered with some of the largest biopharmaceutical companies on the planet to ensure our biosimilars reach those that need them most.

Our current partnerships

Below are some of our currently disclosed partnerships with global and local biotechnology companies.

We have entered a global commercialization agreement with Sandoz AG for the commercialization of our natalizumab biosimilar
We have entered a global commercialization agreement with Sandoz AG for the commercialization of our natalizumab biosimilar

Under the agreement, we are responsible for the development, manufacturing and supply of the collaboration biosimilar. Sandoz have global commercialisation rights.

Learn more
We have entered into a joint venture company, Bioeq, with Santo Holding AG (Strüngmann Group) for the development of the biosimilar Ranibizumab.
We have entered into a joint venture company, Bioeq, with Santo Holding AG (Strüngmann Group) for the development of the biosimilar Ranibizumab.

The biosimilar was originally licensed from Formycon AG and subsequently developed by Bioeq AG

Learn more
Our joint venture company, Bioeq, has entered into a commercialization agreement with Coherus for the biosimilar Ranibizumab
Our joint venture company, Bioeq, has entered into a commercialization agreement with Coherus for the biosimilar Ranibizumab

Coherus BioSciences, Inc. have commercialisation rights to the biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in the United States.

Learn more
Our joint venture company, Bioeq, has entered into a commercialization agreement with Teva for the biosimilar Ranibizumab
Our joint venture company, Bioeq, has entered into a commercialization agreement with Teva for the biosimilar Ranibizumab

Teva Pharmaceutical Industries Ltd have commercialisation rights to the biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in Europe, Canada, Israel and New Zealand.

Learn more

Our areas of interest

We focus on developing biosimilars that will be first to market or where there is a significant market potential. These can be either for blockbuster originators or niche disease areas.

As a company we consistently invest in the start of new biosimilar developments every year based upon expert market analysis, clinical evaluation, and an extensive manufacturing assessment.

Our approach to partnering

Currently, there is no company on the Polish market with scale comparable to ours and with a similar business model. We are able to handle biosimilars from the concept stage to large scale production. We are currently progressing up to 10 biosimilars, of which 2 are closing on market approval. These leading biosimilars are partnered with multiple companies for marketing rights to different territories.

We are always looking to partner with companies that share our ethos of expanding market access of much needed therapeutics, we are especially interested in discussing partnerships with companies who are looking to take on marketing rights for major territories including the US, Europe and Asia.

For more information please get in touch.

Contact us

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.